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Introduction: Contralateral reduction mammaplasty is regularly included in the treatment of breast
cancer patients. We analyzed the incidence of occult breast cancer and high-risk lesions in reduction
mammaplasty specimens of women with previous breast cancer. We also analyzed if timing of reduction
mammaplasty in relation to oncological treatment influenced the incidence of abnormal findings, and
compared if patients with abnormal contralateral histopathology differed from the study population in
terms of demographics.
Materials and methods: The study consisted of 329 breast cancer patients, who underwent symmetrizing
reduction mammaplasty between 1/2007 and 12/2011. The data was retrospectively analyzed for de-
mographics, operative and histopathology reports, oncological treatment, and postoperative follow-up.
Results: Reduction mammaplasty specimens revealed abnormal findings in 68 (21.5%) patients. High-risk
lesions (ADH, ALH, and LCIS) were revealed in 37 (11.7%), and cancer in six (1.9%) patients. Abnormal
histopathology correlated with higher age (p ¼ 0.0053), heavier specimen (p ¼ 0.0491), and with no
previous breast surgery (p < 0.001). Abnormal histopathological findings were more frequent in patients
with reduction mammaplasty performed prior to oncological treatment (p < 0.001), and in patients with
immediate reconstruction (p ¼ 0.0064).
Conclusion: The incidences of malignant and high-risk lesions are doubled compared to patients without
prior breast cancer. Patients with abnormal histopathology cannot be preoperatively identified based on
demographics. If reduction mammaplasty is performed before oncological treatment, the incidence of
abnormal findings is higher. In the light of our results, contralateral reduction mammaplasty with his-
topathological evaluation in breast cancer patients offers a sophisticated tool to catch those patients
whose contralateral breast needs increased attention.
© 2017 Elsevier Ltd. All rights reserved.1. Introduction
Contralateral symmetrizing reduction mammaplasty is regu-
larly included in the operative plan of breast cancer patients. It is
performed simultaneously with mastectomy or cancer resection,
during immediate or delayed breast reconstruction, or later in the
process. Patients with breast cancer history are at some risk of
developing a contralateral breast cancer. Althoughmodern imagingReconstructive Surgery, Uni-
, P.O. Box 266, 00029, HUS,
(P.A. Merkkola-von Schantz).and oncological treatment have lowered the incidence of contra-
lateral cancer to 0.25%e0.75% annually [1e3], it comes as no sur-
prise that occult breast cancer as well as high-risk lesions may be
revealed in reduction mammaplasty specimens. The incidence of
occult cancer in reduction mammaplasties aimed at symmetriza-
tion varies from 0.94% to 5.45% [4e14]. However, the differences in
the definition of clinically relevant breast histopathology, as well as
inclusion of lobular carcinoma in situ (LCIS), lead to discrepancies.
When only invasive cancer and ductal carcinoma in situ (DCIS) are
taken into account, the incidence of occult breast cancer ranges
from 0.94% to 3.64% [4e14] in breast cancer patients.
Our aim was to report the incidence of occult breast cancer and
high-risk lesions in reduction mammaplasty specimens in patients
with a history of breast cancer from a high-volume center. We also
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logical treatment influenced the incidence of abnormal findings in
reduction mammaplasty specimens, and compared if patients with
abnormal histopathology differed from the study population in
terms of demographics.
2. Material and methods
The study population consisted of 329 breast cancer patients,
who underwent symmetrizing reduction mammaplasty in the
Department of Plastic and Reconstructive Surgery, Helsinki Uni-
versity Hospital, between January 2007 and December 2011
including postoperative follow-up until the end of December 2016.
The data was retrieved from patient records and retrospectively
analyzed for demographics, operative and histopathology reports,
oncological treatment, and postoperative follow-up.
Experienced pathologists analyzed histopathology of the spec-
imens. After fixing with formalin, the specimens wereweighed and
examined macroscopically for masses or for areas of increased
density. Specimens were cut into one cm slices, and samples for
tissue blocks were taken frommacroscopically suspicious areas and
evaluated histopathologically. The number of tissue blocks varied
between three and 22, six being the most usual number.
Histopathological findings in reduction mammaplasty speci-
mens were categorized based on consensus statement outlined by
the Cancer Committee of the American Pathologists [15]. Abnormal
histopathological findings in our study included proliferative breast
lesions without atypia, atypical ductal hyperplasia (ADH), atypical
lobular hyperplasia (ALH), lobular carcinoma in situ (LCIS), ductal
carcinoma in situ (DCIS), and invasive cancer. Low-risk lesions
included intraductal papilloma and sclerosing adenosis. High-risk
lesions included ADH, ALH, and LCIS. Invasive cancer and DCIS
were categorized as cancer findings due to their similar clinical
management. All other histopathological findings were defined as
normal breast tissue. For statistical purposes, patients with
abnormal histopathology were categorized to subgroups based on
the most severe finding, e.g. a patient with both low-risk and high-
risk lesions was included in the high-risk group. In 12 (3.6%) pa-
tients, no sample was taken for histopathological analysis. The
percentages of abnormal findings were calculated from the number
of samples available (n ¼ 317).
Primary breast cancers were recorded. For statistical purposes
smaller subgroups, such as papillar, micropapillar, mucinous,
tubular and tubulolobular cancer, were connected to the ductal
cancer group by an experienced pathologist.
Mean values (±SD) were reported for continuous variables.
Pearson's chi-squared test was applied in bivariate analyses be-
tween categorical variables. Mann-Whitney U test was applied for
testing differences in medians between two groups, when variables
did not follow normal distribution. Two-sample t-test and analysis
of variance were used when patient age was compared betweenTable 1
Demographic characteristics of the patients.
Demographic data Normal histo
n ¼ 249
Mean agea 55.8 ± 8.1
Positive smoking history 19 (7.6%)
Previous breast surgerya
 No 26 (56.5%)
 Yes 223 (82.3%)
Mean weight (g) of the specimensa 342.8 ± 256.
Plus-minus values are means ± SD.
a There is a statistical difference in age (p ¼ 0.0053), specimen weights (p
patients with abnormal and normal histopathology.patient groups. P-values less than 0.05 were considered statistically
significant.
3. Results
A total of 329 patients with a mean age of 56.3 ± 8.2 years un-
derwent reduction mammaplasty. Histopathological evaluation of
reduction mammaplasty specimens revealed abnormal findings in
68 (21.5%) patients and normal breast tissue in 249 (78.5%) patients.
In 12 (3.6%) patients, with a mean age of 53.5 ± 6.5 years, no sample
was obtained for histopathological analysis. The mean age (SD),
smoking history, previous breast surgery, and the mean weight (g)
of the specimen of the patients with normal and abnormal histo-
pathology are listed in Table 1. There was a significant difference in
age (p ¼ 0.0053), specimen weights (p ¼ 0.0491) and incidence of
previous breast surgery (p < 0.001) between patients with
abnormal and normal histopathology so that abnormal histopa-
thology correlated with higher age, heavier specimen, and with no
previous breast surgery. The incidences of different forms of pri-
mary cancer in patients undergoing contralateral reduction mam-
maplasty and histopathological evaluation are listed in Table 2.
3.1. Histopathology
Evaluation of reduction mammaplasty specimens revealed
abnormal histopathological findings in 68 (21.5%) patients with a
mean age of 58.9 ± 8.5 years. The incidences of abnormal histo-
pathological findings in reduction mammaplasty specimens are
presented in Table 3. Two simultaneous abnormal findings were
revealed in 12 patients and three simultaneous abnormal findings
in one patient.
In total, low-risk lesions (sclerosing adenosis, intraductal pap-
illoma) were revealed in 35 (11.0%) patients, high-risk lesions (ADH,
ALH, and LCIS) in 37 (11.7%) patients and cancer in six (1.9%) pa-
tients. The incidence of abnormal histopathological findings by age
is presented in Tables 4a and 4b. In age comparisons, for statistical
purposes, patients with abnormal histopathology were categorized
to subgroups based on the most severe finding, e.g. patient with
both low-risk and high-risk lesions was included in the high-risk
group. Abnormal histopathological findings in total (p ¼ 0.0088)
were more frequent with increasing age. Statistical analysis for
smaller subgroups was not reliable due to low number of findings
per different age groups.
3.2. The timing of reduction mammaplasty
Reduction mammaplasty was performed before oncological
treatment in 77 (23.4%) patients and after oncological treatment in
252 (76.6%) patients. Abnormal histopathological findings were
statistically more frequent (p < 0.001) in patients with reduction





6 398.2 ± 254.9
¼ 0.0491) and incidence of previous breast surgery (p < 0.001) between
Table 2
The incidences of different forms of primary cancer in patients undergoing
contralateral reduction mammaplasty and histopathological evaluation.




DCIS 21 (8.4%) 12 (17.6%)
IDC 157 (63.1%) 45 (66.2%)
ILC 45 (18.1%) 8 (11.8%)
IDC and ILC 10 (4.0%) 2 (2.9%)
Other 5 (2.0%) 1 (1.5%)
Unknown 11 (4.4%) 0 (0.0%)
DCIS: Ductal carcinoma in situ, IDC: Invasive ductal cancer, ILC: Invasive lobular
cancer, IDC and ILC: Both Invasive ductal and lobular cancers, Other: Malign Phylloid
Tumor, Both Paget disease and DCIS, or Both Paget disease and IDC.
Table 3
Abnormal histopathological diagnosis in reduction mammaplasty specimens.a
Diagnosis Number of patients %
Sclerosing adenosis 24 7.6%
Intraductal papilloma 12 3.8%
Atypical ductal hyperplasia 30 9.5%
Atypical lobular hyperplasia 5 1.6%
Lobular carcinoma in situ 4 1.3%
Ductal carcinoma in situ 5 1.6%
Ductal cancer 1 0.3%
Lobular cancer 1 0.3%
a Two simultaneous abnormal findings were revealed in 12 patients and three
simultaneous abnormal findings in one patient. One patient had both ductal cancer
and ductal carcinoma in situ finding at the same time in reduction mammaplasty
specimen.
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treatment. The patients receiving neoadjuvant therapy (n¼ 5) were
assigned to the latter group.
3.3. Breast reconstruction
Breast reconstruction was performed in 159 (48.3%) patients, of
which immediate reconstruction in 33 (20.8%) and delayed recon-
struction in 126 (79.2%) patients. The patients undergoing imme-
diate reconstruction after neoadjuvant therapy (n ¼ 2) were
assigned to the first group. In breast reconstruction patients,
contralateral reduction mammaplasty revealed abnormal histo-
pathological findings in 31 (20.3%) patients, and histopathology
was normal in 122 (79.7%) patients. There was a statistical differ-
ence (p ¼ 0.0064) in patients with abnormal histopathology be-
tween immediate and delayed reconstruction so thatTable 4a
Abnormal histopathological findings by age groups.
Finding <40 (n ¼ 10) 40e49 (n ¼ 46)
Normal histopathology 9 (90.0%) 37 (80.4%)
Abnormal histopathologya 1 (10.0%) 9 (19.6%)
a Abnormal histopathological findings (p ¼ 0.0088) were more frequent with increasi
Table 4b
Abnormal histopathological findings by age groups.a
Finding <40 (n ¼ 10) 40e49 (n ¼ 46)
Normal histopathology 9 (90.0%) 37 (80.4%)
Low-risk lesion 1 (10.0%) 1 (2.2%)
High-risk lesion 0 (0.0%) 7 (15.2%)
Cancer 0 (0.0%) 1 (2.2%)
a For statistical purposes, patients with abnormal histopathology were categorized to s
risk lesions was included in the high-risk group.histopathology was abnormal in 15.7% with delayed reconstruction
versus 37.5% with immediate reconstruction.
3.4. Primary cancer
To analyze if primary cancer type affected the incidence of
abnormal histopathological findings in reduction mammaplasty
specimens was not possible due to the small number per primary
cancer type.
3.5. Postoperative follow-up
Postoperative follow-up until the end of December 2016 was
included. The mean follow-up time was 7.4 ± 1.4 years. During this
time, three patients were diagnosed with a new cancer in the
reduced breast. Reduction mammaplasty specimens had revealed
ADH in one, and mastopathia chronica in one of these patients. In
the third case, no sample for histopathological analysis had been
taken. The patient with ADH in the specimens was later diagnosed
with DCIS. The other two were diagnosed with DCIS and invasive
cancer, respectively.
4. Discussion
We detected a considerable number (21.5%) of abnormal histo-
pathological findings in reduction mammaplasty patients with a
previous history of breast cancer. Our earlier study with reduction
mammaplasty patients without a history of breast cancer showed
the incidences of occult breast cancer and high-risk lesions of 1.2%
and 5.5%, respectively [16]. When compared to the present study
(the incidence of cancer 1.9%, the incidence of high-risk lesions
11.7%), the incidences doubled in patients with a history of breast
cancer. Similarly, others [4e13] have noticed that history of breast
cancer increases the incidence of abnormal findings in reduction
mammaplasty specimens. A point worth noticing in breast cancer
patients is that the incidence of abnormal findings in contralateral
reduction mammaplasty is calculated per one breast compared to
e.g. macromastia patients with the incidence calculated per both
breasts. Still, the incidence of abnormal findings often multiplies in
breast cancer patients. Thus, this supports the importance of his-
topathological evaluation of reduction mammaplasty specimens.
Benign breast disease is a prominent predictor of future breast
cancer risk [15,17e26]. Hartmann et al. [26] showed a 29.0% cu-
mulative incidence of breast cancer at 25 years inwomenwith ADH
or ALH, and similarly, King et al. [23] showed a 2.0% annual inci-
dence of breast cancer among women with LCIS and an overall50e59 (n ¼ 143) >60 (n ¼ 118) Total (n ¼ 317)
122 (85.3%) 81 (68.6%) 249 (78.5%)
21 (14.7%) 37 (31.4%) 68 (21.5%)
ng age.
50e59 (n ¼ 143) >60 (n ¼ 118) Total (n ¼ 317)
122 (85.3%) 81 (68.6%) 249 (78.5%)
13 (9.1%) 11 (9.3%) 26 (8.2%)
7 (4.9%) 22 (18.6%) 36 (11.4%)
1 (0.7%) 4 (3.4%) 6 (1.9%)
ubgroups based on the most severe finding, e.g. patient with both low-risk and high-
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high-risk lesions in reduction mammaplasty specimens in patients
with a history of breast cancer is higher compared to patients
without prior breast cancer. Li et al. [7] showed that the frequency
of detecting atypical proliferative lesions in patients with history of
breast cancer is significantly higher than in patients without pre-
vious breast cancer (12.8% versus 4.3%). Also Ishag et al. [9] and
Freedman et al. [12] have demonstrated a higher incidence of high-
risk lesions in breast cancer patients compared to patients without
history of breast cancer, 7.1% versus 0.97%, and 17.9% versus 3.3%,
respectively. As the importance of high-risk lesions for the patients
is clear over time, reduction mammaplasty can capture this patient
group for future surveillance.
In our study, patients with abnormal histopathology were older,
their specimens were heavier, and if previous breast surgery was
conducted, the histopathology was more often normal. In our
previous study with patients without history of breast cancer [16]
we detected similar trend regarding age and specimen weight.
Based on these findings it is difficult to define a certain threshold to
preoperatively catch patients with abnormal histopathology or to
securely say that histopathological examination can be ruled out
based on a certain age group. For example, in this study, in age
group under 50 years old, there were seven (19.4%) patients with
high-risk lesions and one (16.7%) patient with cancer. We do,
however, recommend that the heavier specimen of older patients
might benefit from more frequent sampling. The majority of the
patients with previous breast surgery were operated for breast
cancer before contralateral reduction mammaplasty, and received
postoperative oncological treatment. This may explain the protec-
tive effect of previous breast surgery.
The majority (76.6%) of reduction mammaplasties were per-
formed after oncological treatment. However, abnormal histo-
pathological findings were statistically more frequent in patients
with surgery performed before oncological treatment. This may be
explained by modern imaging and oncological treatment that
lower the incidence of contralateral cancer [1e3]. Also, the use of
chemoprevention for risk management has been shown to reduce
breast cancer incidence among women with atypical hyperplasia
and LCIS at 10 years from 21.3% to 7.5% [25]. Similarly, King et al.
[23] showed a reduction in breast cancer incidence at 10 years from
21% to 12% in women with LCIS on chemoprevention compared to
women with no chemoprevention. Thus, this puts emphasis on
histopathological evaluation of reduction mammaplasty specimens
in breast cancer patients with reduction mammaplasty performed
before oncological treatment.
In our study, breast reconstruction was performed for 48.3% of
the patients. In this patient group, abnormal histopathological
findings were statistically more frequent, if reconstruction was
performed immediately. As we stated above, oncological treatment
seems to play a role in the incidence of abnormal findings in
reduction mammaplasty specimens. In our previous study [27], we
demonstrated that preoperative imaging does not sufficiently
detect high-risk or malignant lesions. Therefore, histopathological
evaluation of reduction mammaplasty specimens seems
mandatory.
We acknowledge some limitations to our study. Due to its
retrospective nature, we could not standardize histopathological
sampling. Nevertheless, this study cohort represents common
plastic surgery practice.
5. Conclusion
Reduction mammaplasty specimens in breast cancer patients
reveal a considerable amount of malignant and high-risk lesions
commonly multiplied compared to patients without prior breastcancer history, and especially frequently if reduction mammaplasty
is performed prior to oncological treatment. In the light of our re-
sults contralateral reduction mammaplasty followed by histo-
pathological evaluation in breast cancer patients offers a
sophisticated tool to catch those patients whose contralateral
breast needs increased attention. This works without going into
needless s.c. risk-reducing bilateral mastectomies and implant
based reconstructions advocated by patients fears for cancer and
industry lead insurance policies, increasing in popularity in many
countries.
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